VivoSim Labs, INC. (VIVS): Entry into a Material Definitive Agreement
VivoSim Labs, INC. (VIVS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On October 13, 2026, Organovo, Inc. (“Organovo”), a wholly-owned subsidiary of VivoSim Labs, Inc. (the “Company”), entered into a Second Amendment to Amended and Restated Lease (the “Amendment”) with San Diego Inspire 2, LLC (
How this was made
The 30-second read
Why it matters
The amendment modestly raises rent and reduces space, a routine corporate action with limited market impact.
Market read
A low‑impact corporate action for a micro‑cap; unlikely to move the stock significantly.
What to watch
Potential future sublease of vacated Suite 202 could generate income, offsetting higher rent.
Background
VivoSim Labs is a micro‑cap biotech company; the 8‑K filing discloses a lease amendment for its principal executive offices.
Ticker impact
VivoSim Labs filed an 8‑K reporting a lease amendment that changes rent and space requirements for its San Diego headquarters.
potential slight downside as investors price in higher occupancy costs
Lease terms affect operating expenses but the dollar amount is modest for a micro‑cap; no immediate catalyst for a large move.
Market effects
Minimal impact on the biotech/health‑tech sector; lease changes are company‑specific.
No broader regional effect; confined to VivoSim's San Diego operations.
Negligible for global markets.
Counterpoint
If the rent reduction offsets the higher base rent, the net cost impact could be neutral, limiting downside risk.
Key entities
- companyVivoSim Labs, Inc.
Issuer of the 8‑K filing.
- subsidiaryOrganovo, Inc.
Wholly‑owned subsidiary executing the lease amendment.
